Laboratory Diagnostics (Global Market)

Laboratory Diagnostics (Russian Market)

Main article: Laboratory diagnostics (Russian market)

Chronicle

2024

Global molecular imaging equipment reached $2.19 billion in a year

In 2024, expenditures in the global molecular imaging equipment market reached $2.19 billion. At the same time, North America dominates, which accounted for more than 40% of global costs. Such data are provided in the Fortune Business Insights review, which TAdviser reviewed in early June 2025.

Molecular imaging is a type of medical diagnosis that allows you to obtain detailed images of biological processes at the cellular and molecular levels. This technology provides a number of advantages over other common methods, such as X-rays and computed tomography (CT). In particular, molecular imaging provides a unique insight into the human body, which helps doctors personalize patient care. For example, such diagnostics provide an opportunity to accurately assess a particular patient's biological response to a particular therapy over time. In addition, molecular imaging allows you to detect diseases at the earliest stages, including determining the location of neoplasms with high accuracy. Molecular imaging helps capture changes at the cellular level - even before the relevant signs can be detected through CT.

𝓲

Фото: Freepik

One of the drivers of the analytics market is called population aging in combination with the growing prevalence of chronic diseases such as Alzheimer's disease, cancer, etc. Accurate diagnosis and tracking of such conditions requires effective imaging tools, including combined positron emission tomography and computed tomography (PET/CT) systems. Such equipment combines advanced technologies and functions, providing high diagnostic accuracy and improved image quality. Technological advances that expand molecular imaging capabilities also have a positive impact on the industry. In addition, artificial intelligence is being actively introduced in the healthcare sector. AI-based systems are capable of analyzing medical images with high accuracy, speeding up results and minimizing human error.

However, there are also restraining factors, one of which is the high cost of modern diagnostic systems. In addition, underdeveloped health infrastructure in some regions limits the wider adoption of molecular imaging techniques.

By system type, the market is segmented into PET, single-photon emission computed tomography (SPECT), etc. In 2024, PET plants provided the largest share of revenue. Geographically, North America leads, accounting for 43.8% of sales, or $0.96 billion. In terms of the application of the systems, such areas as cardiology, oncology, orthopedics, gynecology, neurology, etc., are distinguished. In 2024, the oncology segment dominated, due to the growing prevalence of various types of malignancies. The major players on a global scale are:

• GE Healthcare;
• Siemens Healthineers;
• Koninklijke Philips N.V.;
• Shimadzu;
• Canon Medical Systems;
• Bruker;
• Lantheus Holdings;
• Segami.

Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be 5.9%. As a result, in 2025, the cost of molecular imaging equipment will reach $2.32 billion, and by 2032 it will rise to about $3.46 billion.^[1]

The volume of the global laboratory medical diagnostics market for the year reached $73.99 billion

In 2024, costs in the global market for laboratory medical diagnostics (in vitro) amounted to $73.99 billion. More than a third of this amount fell on the North American region. This is stated in a study by Fortune Business Insights, the results of which were released on April 11, 2025.

The industry demonstrates sustainable development, which is facilitated by several factors. One is the increasing prevalence of acute and chronic diseases, including cardiovascular, genetic and neurological ailments. The use of modern tools for the early detection of such diseases allows doctors to prescribe the most effective treatment courses. Demand is further increasing amid an ageing population: With the rise of older people who are more susceptible to chronic diseases, health care providers are looking for effective means of laboratory medical diagnosis.

Technological advances play an important role in expanding the industry. Integration of automation, artificial intelligence and machine learning improves diagnostic accuracy and responsiveness. Against the background of the introduction of the concept of personalized medicine, diagnostic tools are increasingly used to adapt treatments to individual genetic profiles, which improves the results of therapy. Leading market players invest heavily in research and development activities aimed at improving the characteristics and expanding the capabilities of diagnostic equipment.

Molecular diagnostics is gaining momentum: this is the direction of in vitro diagnostic studies, including all specific methods for analyzing irregular biopolymers - DNA, RNA and proteins. This approach is the basis of personalized medicine. Thanks to molecular diagnostics, it becomes possible to make an early diagnosis and build an optimal treatment regimen that provides the best results. The increase in sales in this segment was facilitated by the pandemic. COVID-19

The study also highlights a number of deterrents. First of all, these are financial difficulties and the lack of an adequate reimbursement policy for diagnostic procedures in developing countries. In addition, in the context of the current macroeconomic situation and geopolitical situation, there may be disruptions in the global supply chain, which negatively affects the availability and cost of raw materials and equipment.

The market in question is segmented into tools as well as reagents and consumables. Type two products bring in the lion's share of revenue, which is explained by the growing number of tests. Analysts estimate that the molecular diagnostics segment held a dominant position in 2024. From a geographical point of view, North America was the leader, which accounted for 37.7% of the global cost, or $27.9 billion. Globally, significant players are named:

• F. Hoffmann-La Roche Ltd.;
• Abbott;
• Thermo Fisher Scientific Inc.;
• Sysmex Corporation;
• Siemens Healthineers AG;
• BD;
• Seegene;
• DiaSorin S.p.A.;
• Quest Diagnostics Incorporated;
• Bio-Rad Laboratories.

In 2025, the cost of laboratory medical diagnostics worldwide is expected to reach $77.73 billion. Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be 6.1%. As a result, by 2032, costs could increase to $117.6 billion.^[2]

Notes